UBS Group Forecasts Strong Price Appreciation for Sight Sciences (NASDAQ:SGHT) Stock

Sight Sciences (NASDAQ:SGHT) had its target price lifted by investment analysts at UBS Group from $7.00 to $8.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. UBS Group’s price target would suggest a potential upside of 15.24% from the company’s previous close.

SGHT has been the subject of a number of other research reports. Citigroup boosted their price target on Sight Sciences from $5.15 to $6.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. Weiss Ratings lowered shares of Sight Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, May 11th. Five research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $7.88.

Sight Sciences Price Performance

SGHT stock traded up $1.39 during midday trading on Thursday, reaching $6.94. The company had a trading volume of 666,782 shares, compared to its average volume of 269,861. Sight Sciences has a 1-year low of $3.19 and a 1-year high of $9.24. The stock has a 50 day moving average price of $5.14 and a 200-day moving average price of $4.90. The company has a debt-to-equity ratio of 0.68, a current ratio of 5.86 and a quick ratio of 5.48. The company has a market capitalization of $377.71 million, a price-to-earnings ratio of -9.80 and a beta of 2.38.

Sight Sciences (NASDAQ:SGHT) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.10. The company had revenue of $23.39 million during the quarter, compared to the consensus estimate of $21.72 million. Sight Sciences had a negative net margin of 46.83% and a negative return on equity of 52.34%. Equities research analysts expect that Sight Sciences will post -0.6 earnings per share for the current year.

Insider Buying and Selling

In other Sight Sciences news, CEO Paul Badawi sold 28,684 shares of the company’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $5.42, for a total value of $155,467.28. Following the sale, the chief executive officer owned 6,122,472 shares in the company, valued at approximately $33,183,798.24. The trade was a 0.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CTO David Badawi sold 7,418 shares of the stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $5.51, for a total value of $40,873.18. Following the completion of the sale, the chief technology officer directly owned 1,982,872 shares of the company’s stock, valued at approximately $10,925,624.72. The trade was a 0.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 58,566 shares of company stock valued at $318,827 over the last 90 days. 30.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in SGHT. AQR Capital Management LLC bought a new stake in shares of Sight Sciences during the 1st quarter valued at about $128,000. Strs Ohio bought a new stake in Sight Sciences in the first quarter worth approximately $158,000. Rhumbline Advisers lifted its stake in Sight Sciences by 9.5% in the first quarter. Rhumbline Advisers now owns 49,797 shares of the company’s stock valued at $120,000 after buying an additional 4,319 shares during the period. Geode Capital Management LLC lifted its stake in Sight Sciences by 5.5% in the second quarter. Geode Capital Management LLC now owns 845,776 shares of the company’s stock valued at $3,494,000 after buying an additional 43,791 shares during the period. Finally, XTX Topco Ltd bought a new position in shares of Sight Sciences during the 2nd quarter worth approximately $67,000. 55.51% of the stock is owned by institutional investors.

More Sight Sciences News

Here are the key news stories impacting Sight Sciences this week:

• Positive Sentiment: Q2 results exceeded expectations: Sight Sciences reported an adjusted loss of $0.08 per share, better than analysts’ expected loss of $0.15-$0.18 and improved from a $0.23 loss a year earlier. Revenue of $23.39 million also surpassed the $21.72 million consensus estimate. Sight Sciences Reports Q2 Loss, Tops Revenue Estimates
• Positive Sentiment: 2026 outlook was raised: The company now expects full-year revenue of $88 million to $92 million, above the roughly $86.1 million Wall Street forecast, while also reducing its adjusted operating-expense guidance. The improved outlook suggests stronger demand and better cost control. Sight Sciences Reports Second Quarter 2026 Financial Results
• Positive Sentiment: FDA cleared OMNI Ultra: The new minimally invasive glaucoma surgery system is designed to perform single-pass canaloplasty followed by trabeculotomy. Its commercial U.S. launch remains planned for the fourth quarter of 2026, creating a potential future product and revenue catalyst. Sight Sciences Receives FDA Clearance of OMNI Ultra
• Positive Sentiment: Broader reimbursement support: Aetna updated its commercial glaucoma policy to recognize Sight Sciences’ OMNI and SION systems as medically necessary for eligible mild-to-moderate open-angle glaucoma patients, potentially improving physician adoption and access. Sight Sciences Announces Aetna Coverage
• Negative Sentiment: Profitability remains a risk: Despite the earnings beat, SGHT continues to report a net loss, negative margins, and negative return on equity. Investors will likely focus on whether revenue growth and expense controls can move the company toward sustainable profitability.

About Sight Sciences

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.